Cognitive Behavioral Therapy

Cognitive behavioral therapy (CBT) is a skill-based talk therapy focused on the relationship between a person’s thoughts, feelings and behaviors. Individuals with depression or anxiety often have pervasive, unrealistic, negative thoughts that adversely shape the way they view themselves, their environment and their prospects for the future. These thoughts can then lead to feelings of depression or anxiety, and if they persist, can interfere with relationships or level of functioning. CBT aims to provide a set of tools that allow the patient to manage negative thoughts by doing things like questioning the validity of these thoughts, altering one’s negative core beliefs, and ultimately changing one’s behaviors. CBT has been widely studied and proven to be effective for those who are able to incorporate these tools into their lives.


Telepsychiatry is the delivery of psychiatric assessment and care via live video conferencing. During telepsychiatry sessions, the patient and provider can see, hear, and interact with one another in real time. Our providers are experts in the treatments most likely to help the depressive or anxious symptoms you are experiencing. Both in-person and telepsychiatry appointments follow the same clinical guidelines; treatment plans, including prescription medicine, can be created and implemented at both.


Spravato (nasal esketamine) has been FDA-approved for the treatment of depression in patients who have not responded to 2 or more treatments. This is the first truly new FDA-approved medication option for depression in 60 years. Esketamine, also called s-ketamine, is “one half” of ketamine ⁠— the other half being r-ketamine, its mirror image molecule. Esketamine is a nasal spray, administered in a certified office setting by psychiatrists, that may more rapidly treat depression than conventional antidepressants. Side effects may be experienced for about an hour while taking it; side effects may include a dreamlike or “floaty” feeling, nausea, headache, or brief and mild elevations in blood pressure. There is a 2-hour observation time after nasal administration. Spravato is covered by some insurers for depression treatment and Actify is actively enrolling in those plans for direct coverage.

Transcranial Magnetic Stimulation

Transcranial Magnetic Stimulation (TMS) is an FDA-approved treatment for depression that is a non-invasive, in-office, well-tolerated procedure. TMS uses an MRI-strength magnetic coil to deliver a low-energy pulse to a targeted area of the brain. This is a non-invasive procedure that does not involve medication. Treatment is delivered on a Monday through Friday basis for 4-6 weeks, and then tapered off. Time in the office is approximately 30 minutes, and patients may drive themselves. Results are typically seen within the first 2-3 weeks. TMS is directly insurance-covered by most plans for treatment resistant depression, but may also be delivered off-label for OCD, PTSD, and other anxiety disorders.

Ketamine Infusion Therapy

Ketamine infusion therapy is a treatment option for depression and some anxiety disorders. Some people do not respond sufficiently to traditional treatment plans, which usually consist of SSRI antidepressants and talk therapy. Patients are connected to an IV and administered a very low dose of ketamine for about 40 minutes. Potential side effects may occur during the infusion including nausea, elevation of blood pressure, dissociation, or headache. Ketamine infusion therapy is a safe, evidence-based, rapid-acting option to help manage treatment-resistant depression and anxiety symptoms. Earlier research and experience with IV ketamine led to the development and approval of Spravato.